247 related articles for article (PubMed ID: 28723516)
1. The Molecular Evolution of Castration-resistant Prostate Cancer.
Ceder Y; Bjartell A; Culig Z; Rubin MA; Tomlins S; Visakorpi T
Eur Urol Focus; 2016 Dec; 2(5):506-513. PubMed ID: 28723516
[TBL] [Abstract][Full Text] [Related]
2. Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor.
Tilki D; Schaeffer EM; Evans CP
Eur Urol Focus; 2016 Dec; 2(5):499-505. PubMed ID: 28723515
[TBL] [Abstract][Full Text] [Related]
3. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
4. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
5. Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer.
Ojo D; Lin X; Wong N; Gu Y; Tang D
Cancers (Basel); 2015 Nov; 7(4):2290-308. PubMed ID: 26593949
[TBL] [Abstract][Full Text] [Related]
6. Steroid hormone synthetic pathways in prostate cancer.
Mostaghel EA
Transl Androl Urol; 2013 Sep; 2(3):212-227. PubMed ID: 25379460
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
8. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar T; Yang JC; Gao AC; Evans CP
Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
[TBL] [Abstract][Full Text] [Related]
10. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
Fujimoto N
J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
[TBL] [Abstract][Full Text] [Related]
11. The changing landscape of advanced and castration resistant prostate cancer: latest science and revised definitions.
Tilki D; Evans CP
Can J Urol; 2014 Apr; 21(2 Supp 1):7-13. PubMed ID: 24775718
[TBL] [Abstract][Full Text] [Related]
12. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
Schalken J; Fitzpatrick JM
BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of androgen receptor alterations in prostate cancer.
Jernberg E; Bergh A; Wikström P
Endocr Connect; 2017 Nov; 6(8):R146-R161. PubMed ID: 29030409
[TBL] [Abstract][Full Text] [Related]
14. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis.
Xu Z; Ma T; Zhou J; Gao W; Li Y; Yu S; Wang Y; Chan FL
Theranostics; 2020; 10(9):4201-4216. PubMed ID: 32226548
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
Cai Z; Chen W; Zhang J; Li H
Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
[TBL] [Abstract][Full Text] [Related]
16. [Castration resistance mechanisms in prostate cancer.].
Martínez-Breijo S; Chantada-Abal V; Aller-Rodríguez M; Bohórquez-Cruz M; Sacristán-Lista F; Ponce-Díaz J; Vázquez-Martul D; Lamas-Díaz L
Arch Esp Urol; 2018 Sep; 71(8):628-638. PubMed ID: 30319123
[TBL] [Abstract][Full Text] [Related]
17. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of
Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
Sung YY; Cheung E
Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
